Cerevel Therapeutics, a leader in neuroscience research, is pleased to announce the appointment of Susan Altschuller, Ph.D. as its new Chief Financial Officer. Dr. Altschuller brings a wealth of experience to the role, having served in similar roles at various pharmaceutical companies. She will join the organization on May 15, 2023, with the goal of furthering Cerevel’s mission to unravel the mysteries of the brain and develop treatments for neurological diseases.
We are thrilled to welcome Susan to the Cerevel family, where her strategic understanding, financial savvy, scientific understanding, and investment community acumen will be highly beneficial as we continue to develop our pipeline of potential therapies.
We are also grateful for Mark Bodenrader’s invaluable contributions as interim CFO during this period of expansive growth. With our strong financial position, Susan’s expertise will play a crucial role in driving the success of our clinical trials and optimizing our cash runway.
Ron Renaud, the incoming president and CEO of Cerevel Therapeutics, is thrilled to collaborate with Susan, who brings deep experience in corporate and commercial finance, investor relations, and strategic growth, as the company works towards seven expected data readouts in 2024. Tony and Ron are confident that Susan is the perfect person to help drive the company’s success.
Dr. Altschuller is excited to join the talented team at Cerevel and help transform the lives of those living with devastating neurological diseases. He is inspired by the creative dealmaking and thoughtful capital formation that Cerevel has achieved thus far and looks forward to pushing boundaries and developing innovative solutions. With exciting days ahead, Dr. Altschuller is ready to make an impact.
About Susan Altschuller, Ph.D.
Dr. Susan Altschuller, who holds both an MBA and a Ph.D., is an experienced financial manager with a successful track record in investor relations and business planning. Her most recent position was that of Chief Financial Officer at ImmunoGen, a groundbreaking biotechnology company leading the way in the creation of antibody-drug conjugates to combat cancer.
Dr. Altschuller has a diverse and impressive career in investor relations, finance, and biomedical engineering. After receiving a BSE in Biomedical Engineering with Honors from Tulane University, she went on to receive a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.
Dr. Altschuller has held positions of increasing responsibility at Biogen, including investor relations, corporate finance, and commercial finance. She was also head of investor relations at Bioverativ, leading all investor-related activities for the launch of the Biogen hemophilia spin-off. Most recently, Dr. Altschuller served as head of investor relations and enterprise finance at Alexion before joining ImmunoGen.
Dr. Altschuller’s involvement in the corporate and philanthropic worlds is far-reaching. Not only does he serve as the audit chair on the Board of Directors of Vestaron Corporation, but he is also a founding Board member of the HNRNP Family Foundation.
About Cerevel Therapeutics
Cerevel Therapeutics is on a mission to unlock the secrets of the brain and develop treatments for neuroscience diseases. Leveraging its expertise in neurocircuitry, the company is creating therapies with a focus on receptor subtype selectivity and a distinctive approach to pharmacology.
Currently, Cerevel Therapeutics has five clinical-stage investigational therapies in its pipeline, plus various preclinical compounds in the works, which could combat a range of illnesses from schizophrenia to Parkinson’s disease.
Based in Cambridge, Mass., Cerevel Therapeutics is continuing to pursue its research and development agenda, as well as looking for new opportunities through collaborations and acquisitions.